SCHEDULE: Prosight Entities Report Stake in OnKure Therapeutics

Prosight Management, LP and affiliated entities have filed a Schedule 13G, reporting a combined beneficial ownership of 2.4% of OnKure Therapeutics, Inc. Class A Common Stock.

Summary

• Prosight Management, LP, along with Prosight Fund, LP, Prosight Plus Fund, LP, Prosight Partners, LLC, and W. Lawrence Hawkins, have jointly filed an amended Schedule 13G.
• This filing reports their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock.
• The total aggregate amount beneficially owned by the reporting persons is 978,992 shares, representing 2.4% of the class.
• This percentage is based on 40,395,480 shares of Common Stock outstanding as of May 4th, 2026, as disclosed in OnKure's Form 10-Q filed on May 5, 2026.
• Prosight Management, LP acts as the general partner and investment manager for Prosight Fund, LP and Prosight Plus Fund, LP.
• Prosight Partners, LLC is the general partner of Prosight Management, LP.
• W. Lawrence Hawkins is the sole manager of Prosight Partners, LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes and not containing operational or financial performance updates.

Positives

• The filing clarifies the ownership structure and stakes held by Prosight entities in OnKure Therapeutics.
• The reporting persons collectively hold a 2.4% stake, indicating a significant but not controlling interest.

Negatives

• The filing does not provide any new financial performance data or operational updates for OnKure Therapeutics.
• The reporting persons disclaim beneficial ownership of securities held by other entities within the group, potentially complicating a unified view of control.

Risks

• The filing does not explicitly mention any risks related to the company's operations or financial health.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement.
• Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act.
• Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and investment funds exceeding a certain ownership threshold. This filing indicates Prosight's ongoing investment in OnKure Therapeutics, but without accompanying operational or financial data, it offers limited insight into the company's performance relative to industry peers.

Related Party Transactions

• Prosight Management, LP is the general partner and investment manager of Prosight Fund, LP and Prosight Plus Fund, LP.
• Prosight Partners, LLC is the general partner of Prosight Management, LP.
• W. Lawrence Hawkins is the sole manager of Prosight Partners, LLC.

Stakeholder Impact

• Shareholders: Provides transparency on significant ownership stakes, which can influence market perception.
• Management: Clarifies the reporting structure of the investment entities.

Next Steps

• Continued monitoring of OnKure Therapeutics' operational and financial performance through their regular SEC filings (e.g., 10-Q, 10-K).

Key Dates

Keywords

OnKure Therapeutics, Prosight Management, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Management, Securities Exchange Act